Atrial Fibrillation

AFib Might Be Far More Common Than We Think

A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease.

UCSF researchers analyzed medical records from 29M adults who received hospital-based care in California from 2005 to 2019 (51yr avg. age, 54% women, 50% White), finding that a whopping 2M (6.8%) of them had been diagnosed with AFib.

  • AFib rates increased dramatically during the study period, from 4.49% in 2005-2009 to 6.82% in 2015-2019.
  • That increase was greatest among younger patients, males, minorities, and patients with hypertension and diabetes. 

When these results are applied across the U.S., the researchers estimate that at least 10.55M Americans are currently diagnosed with AFib, representing 4.48% the U.S. adult population.

  • That’s far higher than previous estimates, including a pair of JAMA and Circulation studies that estimated nationwide AFib rates of 2.26M and 5.1M back in 2000, and forecasted that 3.33M and 7.5M adults would have AFib by 2020.

Since all of these studies only looked at patients who were already diagnosed, true AFib prevalence is likely far higher, with the authors noting that wearable-based arrhythmia detection might drive far more significant diagnosis increases in the future.

The Takeaway

Although few readers are likely surprised that AFib diagnosis is on the rise, this study’s 51% growth rate and 4.48% prevalence estimate truly are shocking, and suggest that we might see a wave of AFib-related care in the future.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square